One of the most complex challenges of 2026 is the rise of Oncology Biosimilars for blockbuster monoclonal antibodies. Unlike simple chemical generics, 2026 biosimilars are highly complex biological products that require specialized manufacturing to mirror the original drug's efficacy. In 2026, the market has seen a wave of approvals for biosimilar versions of leaders like Nivolumab (Opdivo) and...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
คลิกดาวน์โหลด
thai 
English
French
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)
china